替米沙坦联合非那雄胺治疗高血压并发良性前列腺增生的效果以及对血压、IPSS、Qmax、前列腺总体积和残余尿量的影响

摘要

目的 观察替米沙坦联合非那雄胺治疗高血压并发良性前列腺增生的临床效果以及对血压水平、国际前列腺症状评分(international prostate symptom score,IPSS)、最大尿流率(qura of maximum,Qmax)、前列腺总体积和残余尿量的影响.方法 将高血压并发良性前列腺增生患者108例随机分为 A、B、C组各36例.A组给予替米沙坦治疗,B组给予非那雄胺治疗,C组给予替米沙坦联合非那雄胺治疗.随访1年,比较3组治疗效果,同时观察患者血压、IPSS、Qmax、前列腺总体积及残余尿量情况.结果 治疗后3组 SBP、DBP水平均明显低于治疗前(P<0.05),3组间 SBP、DBP、降血压效果及总有效率差异无统计学意义(P>0.05).治疗后3组前列腺体积均明显小于治疗前,B、C组前列腺体积小于 A组,C组前列腺体积明显小于 B组(P<0.05);3组前列腺增生治疗有效率差异无统计学意义(P>0.05).治疗后3组 IPSS及残余尿量明显低于治疗前,Qmax明显高于治疗前,B、C组 IPSS及残余尿量明显低于 A组,Qmax高于 A组,C组 IPSS及残余尿量明显低于 B组,Qmax高于 B组(P<0.05).3组不良反应发生率差异无统计学意义(P>0.05).结论 替米沙坦联合非那雄胺治疗高血压并发良性前列腺增生效果较好,能改善 IPSS,增加 Qmax,降低残余尿量,且不良反应少.%Objective To investigate the clinical efficacy of telmisartan combined with finasteride in treatment of hypertension patients with benign prostatic hyperplasia and on the level of blood pressure,the International Prostate Symptom Score(IPSS),maximum urinary flow rate(Qmax),total prostate volume and residual urine volume.Methods The 108 patients with hypertension and benign prostatic hyperplasia were randomly divided into group A,B and C with 3 6 cases in each group.Group A was given telmisartan treatment,group B was treated with finasteride,and group C was given telmisartan combined finasteride treatment.After 1 years of follow-up,the treatment effect of the 3 groups was compared and the blood pressure,IPSS, Qmax,the total volume of the prostate and the residual urine volume were observed.Results The levels of SBP and DBP in three groups after treatment were significantly lower than those before treatment(P<0.05).There was no significant difference in SBP and DBP levels,blood pressure lowering effect and total effective rate between the three groups(P>0.05).The volume of prostate in group B and C was smaller than that in group A,and the volume of prostate in group C was significantly less than that in group B(P<0.05).There was no significant difference in the effective rates of three groups of prostatic hyperplasia(P>0.05).The IPSS and residual urine volume of the three groups after treatment were significantly lower than that before treatment, Qmaxwas significantly higher than that before treatment.IPSS and residual urine volume in group B and C was significantly lower than the group A,Qmaxhigher than the group A,IPSS and residual urine volume in group C was significantly lower than that of group B,and Qmaxwas higher than that of group B(P<0.05).There was no significant difference in the incidence of adverse reactions among the three groups(P>0.05).Conclusion Telmisartan combined with finasteride treatment of hypertension associated with benign prostatic hyperplasia are better, which can improve the IPSS,increase Qmax,reduce residual urine output,and less adverse reactions.